

PENTEX PHARMA PVT LTD.

NOTICE

To
Shareholders,


NOTICE is hereby given that the Twenty Eighth Annual General Meeting of PENTAX PHARMA PVT LTD will be held on 30th September, 2022 at 4.30 P.m. at the Registered Office of the Company at R No. 7/8, Ghaswala Bldg, G D Road, Dadar , Mumbai - 400 014, to transact the following business.

ORDINARY BUSINESS:

1. To adopt and confirm the Reports of the Auditors' and the Directors' and the Audited Balance Sheet as on 31-03-2022.
2. To appoint the Auditors of the Company and to fix their remuneration.
3. Any other business with the permission of the Chair.

By order of the Board of Directors.

For **M/S PENTEX PHARMA PVT. LTD.**



DIRECTOR

GAUTAM JAIN

DIN-02060629

Place: Mumbai

Date: 14th August, 2022.

DIRECTORS' REPORT

To,
The Shareholders,

PENTEX PHARMA PRIVATE LIMITED

Your Directors have pleasure in presenting this Annual Report on the affairs of the Company together with the audited Statement of Accounts for the year ended 31st March, 2022.

1 The Financial Results

Particulars	For the Year Ended 31.03.2022	For the Year Ended 31.03.2021
Sales and Other Income:	109,873	91,187
Profit Before Taxation, Depreciation & Interest	2,936	4,033
Less: Interest & Financial Charges:	-92	-155
Profit Before Taxation & Depreciation	2,844	3,878
Less: Depreciation	-621	-689
Profit Before Tax	2,223	3,189
Add: Appropriations	-	-
Less: Provision for Taxation (incl. Deferred Tax and Fringe Benefit Tax and Firm Share of Tax Paid)	491	58
Less: Current tax	-500	-825
Profit After Tax	2,215	2,422
Add: Excess Provision for Income Tax	-	-
Add: Balance brought forward from previous year	118,064	115,642
Amount Available for Appropriation	120,279	118,064
Less: Appropriation	-	-
Balance carried to the Balance sheet	120,279	118,064

2 Brief Description of the Company's working during the year /State of Company's Affair

The Company has reported total income of `109,87,304 for the current year as compared to `91,18,688/- in the previous year. The Net Profit for the year under review amounted to `2,21,475 in the current year as compared to Net Profit of `2,42,184 in the previous year.

3 Change in the Nature of Business

There is no change in the nature of the business of the Company done during the Year

4 Event Subsequent to the Date of Financial Statements

No material changes and commitments affecting the financial position of the company occurred between the end of the financial year to which this statement relate and the date of this report

5 Dividend

To strengthen the financial position of the Company the directors regret to declare any dividend.

6 Meetings

During the year the Board of Directors duly met 6 (Six) times on 20th April, 2021; 05th July, 2021; 05th September, 2021; 07th November, 2021; 31st December, 2021 and 25th March, 2022 which were duly convened and held. The intervening gap between the Meetings was within the period prescribed under the Companies Act, 2013

7 Directors and Key Managerial Personnel

Your Company's Board comprises of the following Two Directors

PRAGYAT P LALWANI

GAUTAM S JAIN

There is No change in the Composition of the Board of Directors during the year.

In accordance with the provisions of the Companies Act, 2013 and the Articles of Association of the Company, None of the Director, retire by rotation.

8 Statutory Auditors

M/s. Neerav Sanghavi & Co. Chartered Accountants, statutory auditors of the Company having registration number FRN NO. 139210W hold office until the conclusions of the Annual General Meeting subject to the ratification of the members at every general meeting. The Company has received a certificate from the statutory auditors to the effect that their re-appointment, if made, would be within the limits prescribed.

9 Auditor's Report

The Auditor's Report does not contain any qualification. Notes to Accounts and Auditor's remarks in their report are Self explanatory and do not call for any future comments

10 Extract of Annual Return

As required pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014 an extract of annual return in MGT 9 as a part of this Annual Report as ANNEXURE 'A'.

11 Particulars of Loan, Gurantees or Investment under section 186

NO loans are given, or investment made or guarantee given or security provided by the Company which falls under the provisions of Section 186 of the Companies Act, 2013.

12 Deposit:

The Company has neither accepted nor renewed any deposits during the year under review

13 Particulars of Contracts or arrangements with related Parties

No agreement was entered with related parties by the Company during the current year. There are NO related party transactions which were entered by the Company during the year.

Since NO related party transactions were entered by the Company, FORM AOC- 2 is not applicable to the Company.

14 Conservation of Energy, Technology Absorbtion and Foreign Exchange Earning and outgo

(a) Consevation of Energy

(i)	The Steps taken or impact on conservation of energy	Company's operation does not consume significant amount of energy
(ii)	The Steps taken by the company for utilizing alternate sources of energy	Not Applicable in view of comments in clause (i)
(iii)	The Capital Investment on enrgy conservation equipments	Not Applicable in view of comments in clause (i)

(b) **Technology Absorption**

(i)	The efforts made towards technology absorption	
(ii)	The benefits derived like product improvement cost reduction product development or import substitution	

(c) **Foreign Exchange earnings and outgo**

During the year, the total foreign exchange used was Rs. Nil and the total foreign exchange earned was Rs. Nil

15 Directors' Responsibility Statement


The Directors's Responsibility Statement referred to in clause (c) of Sub- section (3) of Section 134 of the Companies Act,

- (i) That in the preparation of the Annual Accounts, the applicable Accounting Standards had been followed along with proper explanation relating to material departures.
- (ii) That the Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year on 31st March, 2022 and of the profit or loss of the Company for the year ended on that date.
- (iii) That the Directors had taken proper and sufficient care for the maintenance of adequate Accounting records in accordance with the provisions of the Companies Act,2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.
- (iv) That the Directors had prepared the Annual Accounts of the Company on a going concern basis.
- (v) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

16 ACKNOWLEDGEMENT

The directors place on record their sincere appreciation for the assistance and co-operation extended by Bank, its employees, its investors and all other associates and look forward to continue fruitful association with all business partners of the company.

**For and on behalf of the Board of Directors
PENTEX PHARMA PRIVATE LIMITED**



DIRECTOR

Gautam S. Jain

DIN :-02060629

Mumbai

Dated: 14th August,2022



NEERAV SANGHAVI & CO.

CHARTERED ACCOUNTANTS

Neerav M. Sanghavi

B. Com, F.C.A., D.I.S.A. (ICAI)

INDEPENDENT AUDITORS REPORT

To,

THE MEMBERS OF PENTEX PHARMA PRIVATE LIMITED.

1. Report on the Audit of Financial Statements

We have audited the accompanying standalone financial statements of **PENTEX PHARMA PRIVATE LIMITED** which comprise the **Balance sheet as at 31st March, 2022** and also the Statement of Profit and Loss Account for the Year ended and notes to financial statements, including a summary of significant accounting policies.

Opinion:

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

(a) in case of the Balance sheet, of the state of affairs of the Company as at March 31, 2022;

(b) in case of the Statement of Profit & Loss, of the **Profit** for the year ended on that date;

Basis for Opinion

We conducted our audit in accordance with the standards on auditing specified under Section 143 (10) of the Companies Act 2013. Our responsibilities under those Standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Cont...2

Key Audit Matters

1. Key Audit matters are those matters that, in our professional judgments, were most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Reporting of key audit matters as per SA 701, Key Audit Matters are not applicable to the Company as it is an unlisted company.

Information Other than the Financial Statements and Auditors' Report Thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Director's Report including Annexure to Directors' Report, which we obtained prior to the date of this auditors' report and other reports but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on standalone the financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above, and in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information that we obtained prior to the date of this auditors' report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements:

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ('the Act') with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs (financial position) and profit or loss (financial performance) of the company, in accordance with accounting principles generally accepted in India, including the Accounting Standard specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also



includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The board of directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility:

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. But not for the purpose of expressing an opinion on the effectiveness of the entity's internal controls
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.



Report on Other Legal and Regulatory Requirements

The provisions of the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013 is applicable to the Company and we give in 'Annexure A' statement on the matters specified in paragraphs 3 and 4 of the order, to the extent applicable.

1. As required by section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- b) In our opinion, proper books of accounts as required by law have been kept by the Company so far as it appears from our examination of those books;
- c) The Balance Sheet and the Statement of Profit & Loss dealt with by this report are in agreement with the books of account;
- d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;
- e) On the basis of the written representations received from the Directors as on March 31, 2022, taken on record by the Board of Directors, none of the Directors is disqualified as on March 31, 2022 from being appointed as a Director in terms of Section 164 (2) of the Act;
- f) Since the Company's turnover as per last audited financial statements is less than Rs.50 Crores and its borrowings from banks and financial institutions at any time during the year is less than Rs.25 Crores, the Company is exempted from getting an audit opinion with respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls vide notification dated June 13, 2017; and
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position as at balance sheet date;
 - ii. The Company does not have any long term contracts including derivative contracts for which there were any material foreseeable losses.



- iii. There were no amounts which required to be transferred to the Investor Education and Protection Fund by the Company.
- iv. (i) The management has represented that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (ii) The management has represented, that, to the best of it's knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (iii) Based on audit procedures which we considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) contain any material misstatement.
- v. The company has not declared or paid any dividend during the year in contravention of the provisions of section 123 of the Companies Act, 2013.
- vi. With respect to the matter to be included in the Auditors' Report under Section 197(16) of the Act, in our opinion and according to the information and explanations given to us, the limit prescribed by section 197 for maximum permissible managerial remuneration is not applicable to a private limited company.

For **NEERAV SANGHAVI & CO.**
Chartered Accountants



Neerav Sanghavi

Neerav Sanghavi- Proprietor.
F.C.A 107209
Firm Regn. No: 139210W
UDIN:

Place: Mumbai
Date: 14th August, 2022.



NEERAV SANGHAVI & CO.

CHARTERED ACCOUNTANTS

Neerav M. Sanghavi

B. Com, F.C.A., D.I.S.A. (ICAI)

Re: PENTEX PHARMA PRIVATE LIMITED

(ANNEXURE REFERRED TO IN PARAGRAPH 1 OF OUR REPORT OF THE EVEN DATE).
ON THE FINANCIAL STATEMENTS OF THE COMPANY FOR THE YEAR ENDED 31ST
MARCH, 2022.

- 1.)
 - i) The Company has maintained proper records showing full particulars, including quantitative details and situation of its Property, plant and equipment.
 - ii) The Company has a regular programme of physical verification of its Property, plant and equipment by which they are verified in a phased manner over a period of three years. In accordance with this programme, certain property, plant and equipment were verified during the year and no material discrepancies were noticed on such verification. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets.
 - iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties are held in the name of the Company.
 - iv) The company has not revalued its Property, Plant & Equipment or Intangible assets or both during the year.
 - v) No proceedings have been initiated against the company for holding benami property under The Benami Transactions (Prohibition) Act, 1988 and rules made thereunder and the details have been appropriately disclosed in the financial statements.
2. i) As explained to us, the inventories were physically verified during the year at reasonable intervals and no material discrepancies were noticed on physical verification. There are NO opening or closing Inventories.
3. i) According to the information and explanations provided by the management, the Company has not made investments, provided any guarantee or security granted any loans or advance in the nature of loans secured or unsecured to companies, firms, LLps or other parties covered in the register maintained under section 189 of the Act. Accordingly, sub-clause (a), (b) and (c) are not applicable to the Company



Cont...2

: 2 :

4. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of section 185 and 186 of the Act, with respect to the investment made.
5. The Company has not accepted any deposits from public.
6. To the best of our knowledge and as explained, the Central Government has not prescribed maintenance of cost records under sub-section (1) of section 148 of the Act.
7. i) According to the records of the Company, undisputed statutory dues including Provident Fund Income Tax, Sales Tax, Service Tax, duty of Customs, Duty of Excise, Value Added Tax, Cess and other material statutory dues have been generally regularly deposited with the appropriate authorities..According to the information and explanations given to us, No undisputed amounts were outstanding as at March 31, 2022 for a period of more than six months from the date of becoming payable.
ii) According to records of company, there are no dues of income tax or sales tax or wealth tax or service tax or duty of customs or duty of excise or value added tax or cess have not been deposited on account of any dispute.
- 8.) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income-tax Act, 1961 as income during the year.
- 9.) i) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing to any bank as at the balance sheet date. The Company does not have any borrowing from Financial institution or debenture holders during the year.
ii) The company has not been declared as a willful defaulter by any bank or Financial institution or any other lender.
iii) There is No Term Loans Obtained by the company.
iv) The funds raised on short term basis have not been utilized for long term purposes.
v) The Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.
vi) The Company has not raised any loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.



: 3 :

10. i) The Company did not raise any money by way of initial public offer or further public offer (including debt instruments) and term loans during the year. Accordingly, clause (ix) of paragraph 3 of the Order is not applicable to the company.
- ii) The company has not made any preferential allotment or private placement of Shares during the year.
- 11) i) According to the information and explanations given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the year.
- ii) No report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit & Auditors) Rules, 2014 with the Central Government; hence this clause is not applicable.
- 12) The Company is not a Nidhi Company hence this clause is not applicable to the company.
- 13) According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- 14) (a) The Central Government has not prescribed to appoint internal auditor under section 138 of the Act, for any of the services rendered by the Company;
- (b) This clause is not applicable to the company
- 15) In our opinion and according to the information and explanations given to us and based on our examination of the records of the Company, during the year the Company has not entered into non- cash transactions with its directors or persons connected with them and hence provision of section 192 of the Act are not applicable.
- 16) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.



Cont...4

- 17) The company has not incurred cash losses in the financial year and in the immediately.
- 18) There has not been any resignation of the statutory Auditors during the year.
- 19) On the basis of the financial ratios, aging and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, the auditor's knowledge of the Board of Directors and management plans, we are of the opinion that no material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.
- 20) (a) The Provisions of section 135 of Companies Act, 2013 is not applicable to the company;
- 21) Consolidated Financial Statements are not applicable to this company. Accordingly, Clause 3(xxi) of the order is not applicable.

For NEERAV SANGHAVI & CO.
Chartered Accountants



Neerav Sanghavi
Neerav Sanghavi- Proprietor.
F.C.A 107209
Firm Regn. No: 139210W
UDIN:

Place: Mumbai
Date: 14th August, 2022.

Name of the Company :- PENTEX PHARMA PRIVATE LIMITED
Balance Sheet as on 31st March, 2022

(Rs. in '00)

Particulars	Note No.	As on 31st March, 2022	As on 31st March, 2021
		₹	₹
A EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share capital	1	1,820.00	1,820.00
(b) Surplus	2	120,278.67	118,064.08
		-	-
2 Share application money pending allotment			
3 Non-current liabilities			
(a) Long-term borrowings	3	-	4,968.13
(b) Deferred tax liabilities (net)			
(c) Other long-term liabilities	4	-	-
(d) Long-term provisions			
4 Current liabilities			
(a) Short-term borrowings	5	-	-
(b) Trade payables	6	1,935.41	2,961.68
(c) Other current liabilities			-
(d) Short-term provisions	7	437.71	232.74
TOTAL		124,471.80	128,046.63
B ASSETS			
1 Non-current assets			
(a) Property, Plant and Equipment			
(i) Tangible assets	8	8,794.99	9,415.73
(ii) Intangible assets			
(iii) Capital work-in-progress			
(iv) Intangible assets under development			
(v) Fixed assets held for sale			
(b) Non-current investments			
(c) Deferred tax assets (net)		118.87	109.69
(d) Long-term loans and advances	9	2,566.06	6,457.59
(e) Other non-current assets			
2 Current assets			
(a) Current investments			
(b) Inventories			
(c) Trade receivables	10	-	87,159.53
(d) Cash and cash equivalents	11	101,659.62	4,033.21
(e) Short-term loans and advances	12	11,332.26	20,870.89
(f) Other current assets			-
TOTAL		124,471.80	128,046.63
See accompanying notes forming part of the financial statements	20		

As per our Annexed Audit Report of the even date.
For NEERAV SANGHAVI & Co
Chartered Accountants

For PENTEX PHARMA PRIVATE LIMITED.

N. Sanghavi
Neerav Sanghavi-Prop.
F.C.A. - 107209
Firm Regn.No-139210W



Pragnyat Lalwani
DIRECTOR
Pragnyat Lalwani
DIN :-01870792

Gautam Jain
DIRECTOR
Gautam Jain
DIN :-02060629

Mumbai
Dated : 14th August, 2022

Name of the Company :- PENTEX PHARMA PRIVATE LIMITED
Statement of Profit and Loss for the year ended 31 March, 2022

(Rs. in '00)

Particulars	Note No.	For the year ended 31 March, 2022	For the year ended 31 March, 2021
		₹	₹
A CONTINUING OPERATIONS			
1 Revenue from operations (gross)	13	109,494.64	91,186.88
Less: Excise duty		-	-
Revenue from operations (net)		109,494.64	91,186.88
2 Other income	14	378.40	-
3 Total revenue (1+2)		109,873.04	91,186.88
4 Expenses			
(a) Cost of materials consumed		-	-
(b) Purchases of stock-in-trade	15	102,077.66	84,807.43
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade		-	-
(d) Employee benefits expense	16	-	-
(e) Finance costs	17	92.24	154.67
(f) Depreciation and amortisation expense	18	620.72	689.17
(g) Other expenses	19	4,859.25	2,346.34
Total expenses		107,649.86	87,997.62
5 Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)		2,223.17	3,189.26
6 Exceptional items		-	-
7 Profit / (Loss) before extraordinary items and tax (5 ± 6)		2,223.17	3,189.26
8 Extraordinary items		-	-
9 Profit / (Loss) before tax (7 ± 8)		2,223.17	3,189.26
10 Tax expense:			
(a) Current tax expense for current year		500.00	825.21
(b) (Less): MAT credit (where applicable)		-	-
(c) Current tax expense relating to prior years		-	-
(d) Net current tax expense		-	-
(e) Short Provision for Tax		-482.27	-48.32
(f) Deferred Tax Assets		(9.16)	(9.47)
		8.57	767.42
11 Profit / (Loss) from continuing operations (9 ± 10)		2,214.60	2,421.84
B DISCONTINUING OPERATIONS			
12.i Profit / (Loss) from discontinuing operations (before tax)		-	-
12.ii Gain / (Loss) on disposal of assets / settlement of liabilities attributable to the discontinuing operations		-	-
12.iii Add / (Less): Tax expense of discontinuing operations		-	-
(a) on ordinary activities attributable to the discontinuing operations			
(b) on gain / (loss) on disposal of assets / settlement of liabilities			
13 Profit / (Loss) from discontinuing operations (12.i ± 12.ii ± 12.iii)		-	-
C TOTAL OPERATIONS			
14 Profit / (Loss) for the year (11 ± 13)		2,214.60	2,421.84




Name of the Company :- PENTAX PHARMA PRIVATE LIMITED
Statement of Profit and Loss for the year ended 31 March, 2022 (contd.)

	Particulars	Note No.	For the year ended	For the year ended
			31 March, 2022	31 March, 2021
			₹	₹
15.i	Earnings per share (of ` ___/- each):			
	(a) Basic			
	(i) Continuing operations	18.a	1.22	1.33
	(ii) Total operations			
	(b) Diluted			
	(i) Continuing operations	18.b	1.22	1.33
	(ii) Total operations			
15.ii	Earnings per share (excluding extraordinary items) (of ` ___/- each):			
	(a) Basic			
	(i) Continuing operations			
	(ii) Total operations			
	(b) Diluted			
	(i) Continuing operations			
	(ii) Total operations			
See accompanying notes forming part of the financial statements				

As per our Annexed Audit Report of the even date.

For NEERAV SANGHAVI & Co
Chartered Accountants


Neerav Sanghavi-Prop.
F.C.A. - 107209
Firm Regn.No-139210W

Mumbai

Dated : 14th August, 2022



For PENTAX PHARMA PRIVATE LIMITED.


DIRECTOR
Pragnyat Lalwani
DIN :-01870792


DIRECTOR
Gautam Jain
DIN :-02060629

Note 1 Share capital

Particulars	As at 31 March, 2022		As at 31 March, 2021	
	Number of shares	₹	Number of shares	₹
(a) Authorised Equity shares of ₹ 100 each with voting rights	25,000.00	25,000.00	25,000.00	25,000.00
(b) Issued Equity shares of ₹ 100 each with voting rights	1,820.00	1,820.00	1,820.00	1,820.00
(c) Subscribed and fully paid up Equity shares of ₹ 100 each with voting rights	1,820.00	1,820.00	1,820.00	1,820.00

Note 1a Share capital Reconciliation

Particulars								
(i) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:								
Particulars	Opening Balance	Fresh issue	Bonus	ESOP	Conversion	Buy back	Other changes (give details)	Closing Balance
Equity shares with voting rights								
Year ended 31 March, 2022								
- Number of shares	1,820.00	-	-	-	-	-	-	1,820.00
- Amount (₹)	1,820.00	-	-	-	-	-	-	1,820.00
Year ended 31 March, 2021								
- Number of shares	1,820.00	-	-	-	-	-	-	1,820.00
- Amount (₹)	1,820.00	-	-	-	-	-	-	1,820.00

Note 1b Share capital %

(a) Details of shares held by each shareholder holding more than 5% shares:

Class of shares / Name of shareholder	As at 31 March, 2022		As at 31 March, 2021	
	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares
Equity shares with voting rights				
SAMPAT G JAIN	420	23.08	420	23.08
PRAGYAT P LALWANI	910	50.00	910	50.00
GAUTAM S JAIN	490	26.92	490	26.92

Note 2.1 : Reconciliation of number of shares outstanding is set out below:

Particulars	As at 31 March, 2022	As at 31 March, 2021
Equity shares at the beginning of the year	1,820	1,820
Add: Shares issued during the current financial year		
Equity shares at the end of the year	1,820	1,820

Notes:

Note 2.2 : The Company has only one class of equity shares. Each holder of equity shares is entitled to one vote per share.

Note 2.3 : There is no fresh issue or buyback of shares during the year.

Note 2.4 : The Company has only one class of equity shares. Each holder of equity shares is entitled to one vote per share.

Note 2.5 : There is no change in the number of shares outstanding at the beginning and at the end of the year.

Note 2.6 : There is no change in the pattern of shareholding during the year. It is same as the last year.



Name of the Company : PENTEX PHARMA PRIVATE LIMITED

CIN : U24139MH1992PTC068429

Notes forming part of the financial statements

GN 8.1.1 Note 3 Share capital (contd.)

(Rs. in '00)

Ref. No.	Particulars								
	Notes:								
BS 6.A.d	(i) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the								
GN 8.1.1.	? Details to be given for each class of shares separately for Issued, Subscribed and fully paid up and								
	Particulars	Opening Balance	Fresh issue	Bonus	ESOP	Conversion	Buy back	Other changes (give details)	Closing Balance
	Equity shares with voting rights								
	Year ended 31 March, 2022								
	- Number of shares	1,820	-	-	-	-	-	-	1,820
	- Amount (₹)	1,820	-	-	-	-	-	-	1,820
	Year ended 31 March, 2021								
	- Number of shares	1,820	-	-	-	-	-	-	1,820
	- Amount (₹)	1,820	-	-	-	-	-	-	1,820



Name of the Company : PENTEX PHARMA PRIVATE LIMITED

CIN : U24139MH1992PTC068429

Notes forming part of the financial statements

Note 3 Share capital (contd.)

Particulars					
Notes:					
? (ii) Provide detail of the rights, preferences and restrictions attaching to each class of shares (each class of equity and each Arrears of fixed cumulative dividends on preference shares as at 31 March, 2012 ` ____ (As at 31 March, 2011 ` ____)					
(iii) Details of shares held by the holding company, the ultimate holding company, their subsidiaries and associates:					
Particulars	Equity shares with voting rights	Equity shares with differential voting rights	Compulsorily convertible preference shares	Optionally convertible preference shares	Redeemable preference shares
	Number of shares				
As at 31 March, 20X2					
, the holding company	-----NIL-----				
, the ultimate holding company					
Subsidiaries of the holding company					
Associates of the holding company					
Subsidiaries of the ultimate holding company					
Associates of the ultimate holding company					
As at 31 March, 20X1					
, the holding company					
, the ultimate holding company					
Subsidiaries of the holding company					
Associates of the holding company					
Subsidiaries of the ultimate holding company					
Associates of the ultimate holding company					

Details of shares held by each shareholder holding more than 5% shares:

Class of shares / Name of shareholder	As at 31 March, 2022		As at 31 March, 2021	
	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares
Equity shares with voting rights				
PRAGYAT P LALWANI	910	50.00	910	50.00
GAUTAM S JAIN	490	26.92	490	26.92
SAMPATRAJ JAIN	420	23.08	420	23.08
	1820	100	1820	100



Name of the Company :- PENTEX PHARMA PRIVATE LIMITED
Notes forming part of the financial statements

Note 2 Surplus

(Rs. in '00)

Particulars	As at 31 March, 2022	As at 31 March, 2021
	₹	₹
(A) Surplus / (Deficit) in Statement of Profit and Loss		
Opening balance	118,064.07	115,642.24
Add: Profit / (Loss) for the year	2,214.60	2,421.84
Closing balance	120,278.67	118,064.08

Note 3 Long Term Borrowing

(Rs. in '00)

Particulars	As at 31 March, 2022	As at 31 March, 2021
	₹	₹
GAUTAM S JAIN	-	2,454.07
PRAGYAT P LALWANI	-	2,514.06
Total	-	4,968.13

Note 4 Other Long Term liabilities

(Rs. in '00)

Particulars	As at 31 March, 2022	As at 31 March, 2021
	₹	₹
Rent Deposit	-	-
Total	-	-

Note 5 Short-term borrowings

(Rs. in '00)

Particulars	As at 31 March, 2022	As at 31 March, 2021
	₹	₹
Total	-	-



Name of the Company :- PENTEX PHARMA PRIVATE LIMITED
Notes forming part of the financial statements

Note 6 Trade payables

(Rs. in '00)

Particulars	As at 31 March, 2022	As at 31 March, 2021
	₹	₹
Sundry Creditor For Expenses	1,935.41	2,961.68
Total	1,935.41	2,961.68

Note 6(a) : Steps have been taken to identify the suppliers who qualify under the definition of micro and small enterprises, as defined under the Micro, Small and Medium Enterprises Development Act 2006. Since no intimation has been received from the suppliers regarding their status under the said Act as at 31st March 2022, disclosures relating to amounts unpaid as at the year end, if any, have not been furnished. In the opinion of the management, the impact of interest, if any, that may be payable in accordance with the provisions of the Act, is not expected to be material.

Trade payables ageing schedule: AS at 31st March 2022

(Rs. in '00)

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME					-
(ii) Others	1,931.41	4.00			1,935.41
(iii) Disputed dues- MSME					-
(iv) Disputed dues - Others					-

Trade payables ageing schedule: AS at 31st March 2021

(Rs. in '00)

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME					-
(ii) Others	2,887.71	73.97			2,961.68
(iii) Disputed dues- MSME					-
(iv) Disputed dues - Others					-



Name of the Company :- PENTEX PHARMA PRIVATE LIMITED
Notes forming part of the financial statements

Note 7 Short-term provisions

(Rs. in '00)

Particulars	As at 31 March, 2022	As at 31 March, 2021
	₹	₹
TDS on Contract	74.32	89.71
TDS on Professional	200.00	143.03
GST	163.39	-
Total	437.71	232.74

Note 9 Long-term loans and advances

(Rs. in '00)

Particulars	As at 31 March, 2022	As at 31 March, 2021
	₹	₹
Deposits		
MIDC	36.75	36.75
MSBE	839.40	839.40
Loans & Advances :		
CGST	-	176.05
SGST	-	176.05
Net of Provision tax and Tds	1,689.91	5,229.33
Total	2,566.06	6,457.59



PENTEX PHARMA PRIVATE LIMITED.

As per companies Act 2013

Note : 8

Property, plant & equipments as on 31st March, 2022

(Rs. in '00)

NAME OF ASSETS	GROSS BLOCK					RATE OF DEP. %	DEPRECIATION			NET BLOCK	
	AS ON 01/04/2021	ADDITIONS BEFORE SEPT.	ADDITIONS AFTER SEPT.	SALES/Traf. DURING THE YEAR	AS ON 31/03/2022		DEP. UP TO 01/04/2021	DURING THE YEAR	TOTAL Rs..	AS ON 31/03/2022	AS ON 31/03/2021
Land	4,163.04	-	-	-	4,163.04		388.58	55.51	444.09	3,718.95	377,446.00
Factory Building	31,494.42	-	-	-	31,494.42	9.50%	26,135.14	509.00	26,644.14	4,850.28	535,928.00
Machinery	2,738.75	-	-	-	2,738.75	18.10%	2,524.52	39.2102	2,563.73	175.01	21,423.00
Electrical Installation	903.44	-	-	-	903.44	25.89%	883.81	5.00	888.81	14.63	1,963.00
Generator	1,500.00	-	-	-	1,500.00	25.89%	1,494.31	1.00	1,495.31	4.69	569.00
Air Conditioner	270.40	-	-	-	270.40	25.89%	269.39	-	269.39	1.01	101.00
Furnitures & Fixtures	1,267.67	-	-	-	1,267.67	25.89%	1,226.28	11.00	1,237.28	30.39	4,139.00
Computers & Accessories	1,139.57	-	-	-	1,139.57	63.16%	1,139.53	-	1,139.53	0.04	4.00
Total Rs..	43,477.30	-	0.00	-	43,477.30		34,061.57	620.72	34,682.29	8,794.99	941,573.00



Name of the Company :- PENTEX PHARMA PRIVATE LIMITED
Notes forming part of the financial statements

Note 10 Trade receivables

(Rs. in '00)

Particulars	As at 31 March, 2022	As at 31 March, 2021
	₹	₹
Sundry Debtor:-		
Debtors	-	87,159.53
Total	-	87,159.53

Trade Receivables ageing schedule as at 31st March,2022

Particulars	Outstanding for following periods from due date of payment				
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years
(i) Undisputed Trade receivables -considered good					
(i) Undisputed Trade receivables -considered doubtful					
(iii) Disputed trade receivables considered good					
(iv) Disputed trade receivables considered doubtful					

Trade Receivables ageing schedule as at 31st March,2021

Particulars	Outstanding for following periods from due date of payment				
	Less than 6 months	6 months -1 year	1-2 years	2-3 years	More than 3 years
(i) Undisputed Trade receivables -considered good		87,159.53			
(i) Undisputed Trade receivables -considered doubtful					
(iii) Disputed trade receivables considered good					
(iv) Disputed trade receivables considered doubtful					

Note 11 Cash and cash equivalents

(Rs. in '00)

Particulars	As at 31 March, 2022	As at 31 March, 2021
	₹	₹
(a) Cash on hand	2,182.38	1,361.37
(b) Balances with banks :-		
Greater Bombay Co-op Bank Ltd.	6,673.06	6.54
ICICI Bank Ltd	92,804.18	2,665.29
Total	101,659.62	4,033.21

Note 12 Short Term Loans & Advances

(Rs. in '00)

Particulars	As at 31 March, 2022	As at 31 March, 2021
	₹	₹
Staff Advances	300.00	300.00
Advance to Creditors	11,032.26	20,570.89
Total	11,332.26	20,870.89



Name of the Company :- PENTEX PHARMA PRIVATE LIMITED
Notes forming part of the financial statements

Note13 Revenue from operations

(Rs. in '00)

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
	₹	₹
Sale	109,494.64	91,186.88
Total	109,494.64	91,186.88

Note 14 Other income

(Rs. in '00)

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
	₹	₹
Interest on IT Refund	378.40	-
Total	378.40	-

Note 15 Purchase

(Rs. in '00)

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
	₹	₹
Purchase	102,077.66	84,807.43
Total	102,077.66	84,807.43

Note16 Employee benefits expense

(Rs. in '00)

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
	₹	₹
SALARY & WAGES	-	-
Total	-	-

Note 17 Finance costs

(Rs. in '00)

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
	₹	₹
Bank Charges	92.24	154.67
Total	92.24	154.67

Note 18 Other Expences

(Rs. in '00)

Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
	₹	₹
Legal & Proff. Charges	2,200.00	1,907.00
Office Expenses	430.95	127.89
Interest & GST & TDS Late Fess	15.23	92.00
Insurance Premum	342.67	219.45
Factory Expenses	462.13	-
Water Charges	281.94	-
Loading & Unloading Charges	564.95	-
Prof Tax	77.06	-
Rates & Taxes	45.30	-
Staff Welfare	439.02	-
Total	4,859.25	2,346.34



Name of the Company :- PENTEX PHARMA PRIVATE LIMITED

Notes forming part of the financial statements

Note 18 Disclosures under Accounting Standards

Note	Particulars	For the year ended 31 March, 2022	For the year ended 31 March, 2021
		₹	₹
18	Earnings per share		
	Basic		
18.a	<u>Continuing operations</u>		
	Net profit / (loss) for the year from continuing operations	2,214.60	2,421.84
	Less: Preference dividend and tax thereon		
	Net profit / (loss) for the year from continuing operations attributable to the equity shareholders	2,214.60	2,421.84
	Weighted average number of equity shares	1,820.00	1,820.00
	Par value per share		
	Earnings per share from continuing operations - Basic	1.22	1.33
	<u>Total operations</u>		
	Net profit / (loss) for the year		
	Less: Preference dividend and tax thereon		
	Net profit / (loss) for the year attributable to the equity shareholders		
	Weighted average number of equity shares		
	Par value per share		
	Earnings per share - Basic		
	<u>Diluted</u>		
18.b	<u>Continuing operations</u>		
	Net profit / (loss) for the year from continuing operations	2,214.60	2,421.84
	Less: Preference dividend and tax thereon		
	Net profit / (loss) for the year attributable to the equity shareholders from continuing operations	2,214.60	2,421.84
	Add: Interest expense and exchange fluctuation on convertible bonds (net)		
	Profit / (loss) attributable to equity shareholders from continuing operations (on dilution)	2,214.60	2,421.84
	Weighted average number of equity shares for Basic EPS		
	Add: Effect of warrants, ESOPs and Convertible bonds which are dilutive		
	Weighted average number of equity shares - for diluted EPS	1,820.00	1,820.00
	Par value per share		
	Earnings per share, from continuing operations - Diluted	1.22	1.33



PENTAX PHARMA PRIVATE LIMITED.**NOTES FORMING PART OF FINANCIAL STATEMENT FOR THE YEAR ENDED**
31st MARCH, 2022.**1. CORPORATE INFORMATION:**

To carry on the business of manufacturers producers, Exporter, importer, buyer and seller of and dealers in pharmaceuticals medical chemical etc.

2. SIGNIFICANT ACCOUNTING POLICIES**a. ACCOUNTING ASSUMPTIONS:**

The financial accounts are prepared under the historical cost convention on the accrual basis of accounting.

b. FIXED ASSETS:

Cost of fixed assets comprises of purchase price, duties, levies and any directly attributable cost of bringing the asset to its working condition for the intended use. However, it does not include any taxes or duties which are subsequently recoverable from respective authorities.

c. DEPRECIATION:

Depreciation on the assets has been provided on written down value method and the same is calculated at the rates prescribed in Schedule II of the Companies Act,2013.

d. COST AND BENEFITS:

Costs are charged to revenue in the year in which benefits accrue to the company and/or in the year in which the resultant assets are created and put to effective use.

e. RECOGNITION OF INCOME AND EXPENDITURE:

Income & Expenditure, unless otherwise stated, are recognized and accounted for on accrual basis.

f. INVENTORIES:

The Closing Stock is valued At Cost or net realizable value whichever is lower and is as certified by the Directors.

g. INVESTMENTS:

Investments are shown at cost.

h. SALES:

Sales do not include Value Added Tax and GST.

i. RETIREMENT BENEFITS:

The liability for retirement benefits including gratuity in respect of employees is accounted for on cash basis.

j. DIVIDEND:

No Provision is made for Dividend since directors have not proposed any dividend.

k. TAXATION:

Provision for taxation has been made in accordance with the Income Tax Laws relevant for the year.

l. SUNDRY DEBTORS, LOANS:

Doubtful Debts / Advances are written off in the year in which these are considered to be irrecoverable.

m. CONTINGENT LIABILITY:

No provision is made for liabilities, which are contingent in nature, but if material, it is disclosed by way of note.

3. Accounting Standard 22 issued by the Institute of Chartered Accountants of India is applicable to the Company w.e.f 1.4.2002 Deferred Tax Asset as on 1-4-2021 was Rs.10976/- and Deferred Tax Assets for the year is Rs 916. There is a total Deferred Tax Asset of Rs 11,892/- at the year end on account of difference in depreciation as per Companies Act 2013 and Income Tax Act Books of accounts. The year end position is as follows

SUMMARY As On 31st March, 2022

Items	DTA	DTL
Depreciation	11,892	0
Loss on Sale of Asset Disallowed	0	0
Business Loss	0	0
Unabsorbed Depreciation	0	0
U/s. 40a Disallowance	0	0
U/s.43B Disallowance	0	0
Total DTA / DTL Bifurcation	11,892	0

5. There are no Foreign Currency Transactions during the year.
6. Previous years figures have been regrouped and rearranged wherever necessary.
7. Debit & Credit balances are subject to confirmation by the respective parties.

8. Additional Regulatory Info

Title deeds:

All Title deeds of Immovable Property are held in name of the Company

Revalued Property, Plant and Equipment:

The Company has not revalued its Property, Plant and Equipment.

Loans or Advances:

There is no Loans or Advances in the nature of loans granted to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013,) either severally or jointly with any other person.

Capital-work-in progress / Intangible Assets:

There is no Capital-work-in progress / Intangible assets under development (ITAUD).

Borrowings from Banks or Financial Institutions:

The Company has no borrowings from banks or financial institutions on the basis of security of current Asset.

Benami Property:

The Company does not hold any Benami Property and No proceedings have been initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988).

Wilful defaulter:

The company is not declared Wilful defaulter by any bank or financial Institution or other lender.

Relationship with any struck Off Company:

Company has no Relationship with any struck Off Company.

Utilisation of Borrowed funds and share premium:

The company has not advanced or loaned or invested any funds in intermediaries.

Registrar of Companies:

There are No charges or satisfaction which are to be registered with Registrar of Companies beyond the statutory period.

Compliance with approved Scheme(s) of Arrangements:

There is no Scheme of Arrangements by the Company

Following Ratios to be disclosed: -

<u>Ratio Analysis:</u>	<u>A.Y.2022-23</u>	<u>P.Y.2021-22</u>
(a) Current Ratio	47.66	35.12
(b) Debt-Equity Ratio	0.02	0.03
(c) Debt Service Coverage Ratio	-	-
(d) Return on Equity Ratio	0.02	0.02-
(e) Inventory turnover ratio	-	-
(f) Trade Receivables turnover ratio	2.51	1.00
(g) Trade payables turnover ratio	41.69	15.29
(h) Net capital turnover ratio	0.99	0.84
(i) Net profit ratio	0.02	0.03
(j) Return on Capital employed	0.02	0.03
(k) Return on investment	-	-

5. RELATED PARTY TRANSACTIONS

Particulars	As on 31.03.22	As on 31.03.21
Sales :-		
Seshaasai Business Forms Private Limited	1,09,49,464/-	91,18,687/-
Total Rs..	1,09,49,464/-	91,18,687/-

Signature to *Schedule*

For PENTAX PHARMA PRIVATE LIMITED.

**DIRECTOR
GAUTAM JAIN
DIN-02060629**

Mumbai.

Date: 14th August , 2022.